Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)

Competitors to Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)

Amgen Inc. 

Teva and Amgen compete primarily in the biopharmaceutical sector, particularly in the area of biosimilars. Amgen, with its strong pipeline of innovative biologics, often outcompetes Teva when it comes to new and lucrative biologic drugs. Teva's strategy to focus on biosimilars is aimed at capturing a share of the market dominated by original biologic products, but Amgen’s established presence, extensive research capabilities, and innovative product line typically give it an edge. Amgen’s strong financial position and R&D investment also allow it to lead in the development of new drugs that can threaten Teva's market position.

Bristol-Myers Squibb 

Bristol-Myers Squibb (BMS) and Teva compete in certain therapeutic areas, particularly in oncology and immunology. BMS, as a leading biotech company, has a robust pipeline of innovative and patented products, giving it a competitive edge in the market for new therapies, while Teva aims to capture value through generic versions of such drugs once they go off-patent. The difference in their business models, with BMS focusing on breakthrough therapies and Teva on cost-effective generics, leads them to compete more on the basis of timing and product release rather than direct head-to-head competition. In this regard, BMS generally holds a stronger position due to its focus on innovation.

Mylan N.V.

Teva and Mylan are major players in the generic pharmaceuticals market, often competing for the same biosimilar and generic drug approvals. Both companies have extensive portfolios of generic medications with a focus on reducing healthcare costs. Mylan has made significant strides with its EpiPen products and its global reach, which has allowed it to gain a stronger foothold in the US market, especially with its combination products. Mylan's strategic mergers, such as that with Upjohn, have enhanced its competitive stance against Teva, which has faced challenges in maintaining market share in certain segments.

Pfizer Inc. 

While Teva primarily focuses on generics and specialty medications, Pfizer operates in the branded pharmaceuticals sector, producing a wide range of innovative drugs. They compete indirectly in the sense that Teva often creates generic versions of Pfizer's established products after patent expiration. However, Pfizer's continuous investment in research and development leads to the emergence of new, patented drugs that can overshadow Teva's generics. The scale of Pfizer's marketing and sales force, combined with its vast portfolio, provides a competitive advantage over Teva's core focus on generic medications.

Sandoz (a Novartis division)

Teva and Sandoz, as prominent generics producers, often find themselves competing directly in the field of generic pharmaceuticals. Sandoz leverages the backing of its parent company, Novartis, allowing it access to robust R&D resources and a diverse portfolio of medications. While Teva has a broad generic lineup, Sandoz is continually innovating in the biosimilar space, particularly with its oncology products, which heightens competition in therapeutic areas where they both operate. Sandoz's established reputation and investment in complex generics position it favorably against Teva.